The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Bristol-Myers Squibb's revenues will compress -26.1% and EPS will contract -34.4%.
The average estimate for revenue is $3.88 billion. On the bottom line, the average EPS estimate is $0.42.
Last quarter, Bristol-Myers Squibb reported revenue of $4.19 billion. GAAP reported sales were 23% lower than the prior-year quarter's $5.45 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.47. GAAP EPS of $0.56 for Q4 were 12% higher than the prior-year quarter's $0.50 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 76.4%, 120 basis points better than the prior-year quarter. Operating margin was 21.5%, 840 basis points worse than the prior-year quarter. Net margin was 22.1%, 650 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $16.54 billion. The average EPS estimate is $1.83.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,677 members out of 1,793 rating the stock outperform, and 116 members rating it underperform. Among 505 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 488 give Bristol-Myers Squibb a green thumbs-up, and 17 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bristol-Myers Squibb is hold, with an average price target of $34.53.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Bristol-Myers Squibb. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Bristol-Myers Squibb to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Top Healthcare Stocks to Buy in January
These prominent drug developers look to be enticing buys this month.
Should You Buy Bristol-Myers Squibb Stock in 2018?
Bristol lagged behind its peers in 2017. Can its stock rebound in 2018?
Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb
Which stock wins in a head-to-head match-up between these two big drugmakers?